CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 2984
Fatemeh Sharifi, Ozlem Yesil-Celiktas, Aslihan Kazan, Sushila Maharjan, Saghi Saghazadeh, Keikhosrow Firoozbakhsh, Bahar Firoozabadi, Yu Shrike Zhang. A hepatocellular carcinomabone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles[J]. Journal of Zhejiang University Science D, 2020, 3(3): 189-202.
@article{title="A hepatocellular carcinomabone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles",
author="Fatemeh Sharifi, Ozlem Yesil-Celiktas, Aslihan Kazan, Sushila Maharjan, Saghi Saghazadeh, Keikhosrow Firoozbakhsh, Bahar Firoozabadi, Yu Shrike Zhang",
journal="Journal of Zhejiang University Science D",
volume="3",
number="3",
pages="189-202",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1007/s42242-020-00074-8"
}
%0 Journal Article
%T A hepatocellular carcinomabone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles
%A Fatemeh Sharifi
%A Ozlem Yesil-Celiktas
%A Aslihan Kazan
%A Sushila Maharjan
%A Saghi Saghazadeh
%A Keikhosrow Firoozbakhsh
%A Bahar Firoozabadi
%A Yu Shrike Zhang
%J Journal of Zhejiang University SCIENCE D
%V 3
%N 3
%P 189-202
%@ 1869-1951
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1007/s42242-020-00074-8
TY - JOUR
T1 - A hepatocellular carcinomabone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles
A1 - Fatemeh Sharifi
A1 - Ozlem Yesil-Celiktas
A1 - Aslihan Kazan
A1 - Sushila Maharjan
A1 - Saghi Saghazadeh
A1 - Keikhosrow Firoozbakhsh
A1 - Bahar Firoozabadi
A1 - Yu Shrike Zhang
J0 - Journal of Zhejiang University Science D
VL - 3
IS - 3
SP - 189
EP - 202
%@ 1869-1951
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1007/s42242-020-00074-8
Abstract: We report the development of a metastasis-on-a-chip platform to model and track hepatocellular carcinoma (HCC)bone metastasis and to analyze the inhibitory effect of an herb-based compound, thymoquinone (TQ), in hindering the migration of liver cancer cells into the bone compartment. The bioreactor consisted of two chambers, one accommodating encapsulated HepG2 cells and one bone-mimetic niche containing hydroxyapatite (HAp). Above these chambers, a microporous membrane was placed to resemble the vascular barrier, where medium was circulated over the membrane. It was observed that the liver cancer cells proliferated inside the tumor microtissue and disseminated from the HCC chamber to the circulatory flow and eventually entered the bone chamber. The number of metastatic HepG2 cells to the bone compartment was remarkably higher in the presence of HAp in the hydrogel. TQ was then used as a metastasis-controlling agent in both free form and encapsulated nanoparticles, to analyze its suppressing effect on HCC metastasis. Results indicated that the nanoparticle-encapsulated TQ provided a longer period of inhibitory effect. In summary, HCCbone metastasis-on-a-chip platform was demonstrated to model certain key aspects of the cancer metastasis process, hence corroborating the potential of enabling investigations on metastasis-associated biology as well as improved anti-metastatic drug screening.
Open peer comments: Debate/Discuss/Question/Opinion
<1>